23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

Active as of 2024-04-27

Generated Narrative: Citation

Resource Citation "179615" Version "1" Updated "2023-11-26 18:53:59+0000"

url: https://fevir.net/resources/Citation/179615

identifier: FEvIR Object Identifier/179615, https://pubmed.ncbi.nlm.nih.gov/23306100

version: 1.0.0-ballot

title: 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

status: active

date: 2024-04-27 20:42:39+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')

Medline Base (Citation Artifact Classifier#medline-base)

jurisdiction: World (m49.htm#001)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2013-03-25

lastReviewDate: 2022-12-08

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source (Citation Classification Type#citation-source)
classifier: MEDLINE ()

classification
type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)
classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)

currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of ppublish (Citation Status Type#pubmed-publication-status-ppublish)

statusDate
activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)
period: ?? --> 2013-01-12 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)
period: ?? --> 2013-01-12 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)
period: ?? --> 2013-03-26 06:00:00+0000

citedArtifact
identifier: https://pubmed.ncbi.nlm.nih.gov/23306100, https://doi.org/10.1016/S1470-2045(12)70560-0, pii/S1470-2045(12)70560-0
relatedIdentifier: https://clinicaltrials.gov/NCT00104715
Titles
- Type Language Text
* Primary title (Title Type#primary) English (Tags for the Identification of Languages#en) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Abstracts
- Text Copyright
* **BACKGROUND:** Early chemotherapy might improve the overall outcomes of patients with metastatic non-castrate (ie, hormone-sensitive) prostate cancer. We investigated the effects of the addition of docetaxel to androgen-deprivation therapy (ADT) for patients with metastatic non-castrate prostate cancer. **METHODS:** In this randomised, open-label, phase 3 study, we enrolled patients in 29 centres in France and one in Belgium. Eligible patients were older than 18 years and had histologically confirmed adenocarcinoma of the prostate and radiologically proven metastatic disease; a Karnofsky score of at least 70%; a life expectancy of at least 3 months; and adequate hepatic, haematological, and renal function. They were randomly assigned to receive to ADT (orchiectomy or luteinising hormone-releasing hormone agonists, alone or combined with non-steroidal antiandrogens) alone or in combination with docetaxel (75 mg/m(2) intravenously on the first day of each 21-day cycle; up to nine cycles). Patients were randomised in a 1:1 ratio, with dynamic minimisation to minimise imbalances in previous systemic treatment with ADT, chemotherapy for local disease or isolated rising concentration of serum prostate-specific antigen, and Glass risk groups. Patients, physicians, and data analysts were not masked to treatment allocation. The primary endpoint was overall survival. Efficacy analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00104715. **FINDINGS:** Between Oct 18, 2004, and Dec 31, 2008, 192 patients were randomly allocated to receive ADT plus docetaxel and 193 to receive ADT alone. Median follow-up was 50 months (IQR 39-63). Median overall survival was 58·9 months (95% CI 50·8-69·1) in the group given ADT plus docetaxel and 54·2 months (42·2-not reached) in that given ADT alone (hazard ratio 1·01, 95% CI 0·75-1·36). 72 serious adverse events were reported in the group given ADT plus docetaxel, of which the most frequent were neutropenia (40 [21%]), febrile neutropenia (six [3%]), abnormal liver function tests (three [2%]), and neutropenia with infection (two [1%]). Four treatment-related deaths occurred in the ADT plus docetaxel group (two of which were neutropenia-related), after which the data monitoring committee recommended treatment with granulocyte colony-stimulating factor. After this recommendation, no further treatment-related deaths occurred. No serious adverse events were reported in the ADT alone group. **INTERPRETATION:** Docetaxel should not be used as part of first-line treatment for patients with non-castrate metastatic prostate cancer. **FUNDING:** French Health Ministry and Institut National du Cancer (PHRC), Sanofi-Aventis, AstraZeneca, and Amgen. Copyright © 2013 Elsevier Ltd. All rights reserved.
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Lancet Oncol. 2013 Feb;14(2):104-5
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/23306099/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/23306099
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Nat Rev Urol. 2013 Mar;10(3):123
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/23358518/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/23358518
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: J Urol. 2013 Dec;190(6):2094
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/24209521/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/24209521
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Urol Oncol. 2013 Nov;31(8):1845
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/24210084/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/24210084
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Actas Urol Esp. 2017 Jul - Aug;41(6):347-351
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/28214037/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/28214037
publicationForm
PublishedIns
- Type Identifier Title PublisherLocation
* Periodical (Published In Type#D020492) Electronic ISSN Type/1474-5488, ISOAbbreviation/Lancet Oncol, ISSN Linking/1470-2045, Medline Title Abbreviation/Lancet Oncol, NLM Unique ID/100957246 The Lancet. Oncology England
citedMedium: Internet (Cited Medium#internet)
volume: 14
issue: 2
articleDate: 2013-02
publicationDateText: 2013-Feb
language: English (Tags for the Identification of Languages#en)
pageString: 149-58
publicationForm
citedMedium: Internet without issue (Cited Medium#internet-without-issue)
articleDate: 2013-01-08
webLocation
classifier: Abstract (Artifact Url Classifier#abstract)
url: https://pubmed.ncbi.nlm.nih.gov/23306100/
webLocation
classifier: DOI Based (Artifact Url Classifier#doi-based)
url: https://doi.org/10.1016/S1470-2045(12)70560-0
classification
type: Publishing Model (Cited Artifact Classification Type#publishing-model)
classifier: Print Electronic (Citation Artifact Classifier#Print-Electronic)
classification
type: Chemical (Cited Artifact Classification Type#chemical)
classifier: Androgen Antagonists (#D000726), Taxoids (#D043823), Docetaxel (chemical-substances#15H5577CQD; #D000077143)
classification
type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)
artifactAssessment:

artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Combined Chemotherapy Protocols (#D000971)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Disease-Free Survival (#D018572)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Docetaxel (#D000077143)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Middle Aged (#D008875)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Orchiectomy (#D009919)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Taxoids (#D043823)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
classification
type: Publication Type (Cited Artifact Classification Type#publication-type)
classifier: Clinical Trial, Phase III (#D017428), Journal Article (#D016428), Randomized Controlled Trial (#D016449), Research Support, Non-U.S. Gov't (#D013485)
classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: Journal Article (Citation Artifact Classifier#D016428)
artifactAssessment: : Classifier added by Computable Publishing LLC
classification
type: Citation Subset (Cited Artifact Classification Type#citation-subset)
classifier: IM (elements_descriptions.html#citationsubset#IM)
contributorship
complete: true
entry
contributor:

name: Gwenaelle Gravis
forenameInitials: G
affiliation: : Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. gravisg@ipc.unicancer.fr
entry
contributor:

name: Karim Fizazi
forenameInitials: K
entry
contributor:

name: Florence Joly
forenameInitials: F
entry
contributor:

name: Stéphane Oudard
forenameInitials: S
entry
contributor:

name: Franck Priou
forenameInitials: F
entry
contributor:

name: Benjamin Esterni
forenameInitials: B
entry
contributor:

name: Igor Latorzeff
forenameInitials: I
entry
contributor:

name: Remy Delva
forenameInitials: R
entry
contributor:

name: Ivan Krakowski
forenameInitials: I
entry
contributor:

name: Brigitte Laguerre
forenameInitials: B
entry
contributor:

name: Fréderic Rolland
forenameInitials: F
entry
contributor:

name: Christine Théodore
forenameInitials: C
entry
contributor:

name: Gael Deplanque
forenameInitials: G
entry
contributor:

name: Jean Marc Ferrero
forenameInitials: JM
entry
contributor:

name: Damien Pouessel
forenameInitials: D
entry
contributor:

name: Loïc Mourey
forenameInitials: L
entry
contributor:

name: Philippe Beuzeboc
forenameInitials: P
entry
contributor:

name: Sylvie Zanetta
forenameInitials: S
entry
contributor:

name: Muriel Habibian
forenameInitials: M
entry
contributor:

name: Jean François Berdah
forenameInitials: JF
entry
contributor:

name: Jerome Dauba
forenameInitials: J
entry
contributor:

name: Marjorie Baciuchka
forenameInitials: M
entry
contributor:

name: Christian Platini
forenameInitials: C
entry
contributor:

name: Claude Linassier
forenameInitials: C
entry
contributor:

name: Jean Luc Labourey
forenameInitials: JL
entry
contributor:

name: Jean Pascal Machiels
forenameInitials: JP
entry
contributor:

name: Claude El Kouri
forenameInitials: C
entry
contributor:

name: Alain Ravaud
forenameInitials: A
entry
contributor:

name: Etienne Suc
forenameInitials: E
entry
contributor:

name: Jean Christophe Eymard
forenameInitials: JC
entry
contributor:

name: Ali Hasbini
forenameInitials: A
entry
contributor:

name: Guilhem Bousquet
forenameInitials: G
entry
contributor:

name: Michel Soulie
forenameInitials: M

Generated Narrative: Practitioner #author0
name: Gwenaelle Gravis

Generated Narrative: Practitioner #author1
name: Karim Fizazi

Generated Narrative: Practitioner #author2
name: Florence Joly

Generated Narrative: Practitioner #author3
name: Stéphane Oudard

Generated Narrative: Practitioner #author4
name: Franck Priou

Generated Narrative: Practitioner #author5
name: Benjamin Esterni

Generated Narrative: Practitioner #author6
name: Igor Latorzeff

Generated Narrative: Practitioner #author7
name: Remy Delva

Generated Narrative: Practitioner #author8
name: Ivan Krakowski

Generated Narrative: Practitioner #author9
name: Brigitte Laguerre

Generated Narrative: Practitioner #author10
name: Fréderic Rolland

Generated Narrative: Practitioner #author11
name: Christine Théodore

Generated Narrative: Practitioner #author12
name: Gael Deplanque

Generated Narrative: Practitioner #author13
name: Jean Marc Ferrero

Generated Narrative: Practitioner #author14
name: Damien Pouessel

Generated Narrative: Practitioner #author15
name: Loïc Mourey

Generated Narrative: Practitioner #author16
name: Philippe Beuzeboc

Generated Narrative: Practitioner #author17
name: Sylvie Zanetta

Generated Narrative: Practitioner #author18
name: Muriel Habibian

Generated Narrative: Practitioner #author19
name: Jean François Berdah

Generated Narrative: Practitioner #author20
name: Jerome Dauba

Generated Narrative: Practitioner #author21
name: Marjorie Baciuchka

Generated Narrative: Practitioner #author22
name: Christian Platini

Generated Narrative: Practitioner #author23
name: Claude Linassier

Generated Narrative: Practitioner #author24
name: Jean Luc Labourey

Generated Narrative: Practitioner #author25
name: Jean Pascal Machiels

Generated Narrative: Practitioner #author26
name: Claude El Kouri

Generated Narrative: Practitioner #author27
name: Alain Ravaud

Generated Narrative: Practitioner #author28
name: Etienne Suc

Generated Narrative: Practitioner #author29
name: Jean Christophe Eymard

Generated Narrative: Practitioner #author30
name: Ali Hasbini

Generated Narrative: Practitioner #author31
name: Guilhem Bousquet

Generated Narrative: Practitioner #author32
name: Michel Soulie

Generated Narrative: ArtifactAssessment #meshHeading0
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Combined Chemotherapy Protocols (#D000971)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Disease-Free Survival (#D018572)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Docetaxel (#D000077143)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Middle Aged (#D008875)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Orchiectomy (#D009919)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Taxoids (#D043823)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component